Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Eli Lilly acquires promising PI3Kα inhibitor from Scorpion Therapeutics Eli Lilly and Company (Lilly) has announced a significant acquisition of Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program, a… byPallavi MadhirajuJanuary 15, 2025